Home / Biopharma / Stocks Tumbling on Lethargic Results: Endo International (NASDAQ:ENDP), Novavax (NASDAQ:NVAX)

Stocks Tumbling on Lethargic Results: Endo International (NASDAQ:ENDP), Novavax (NASDAQ:NVAX)

Following previous ticker characteristics, Endo International plc (NASDAQ:ENDP) also run on active notice, stock price rose 3.14% after traded at $23.66 in most recent trading session.

ENDP has price to earnings ratio at unstated figure and the price to current year EPS stands at -482.50%. Whereas the traders who further want to see about this, may be interested to see Price to next year’s EPS that would be 9.24%. The earning yield also gives right direction to lure investment. Moving toward ratio analysis, it has current ratio of 0.90 and quick ratio was calculated as 0.70. The debt to equity ratio appeared as 1.33 for seeing its liquidity position.

Taking notice on volatility measures, price volatility of stock was 3.09% for a week and 5.02% for a month. The price volatility’s Average True Range for 14 days was 0.97. On these bases, analysts would recommend this stock as an “Active Revolving Stocks.” The firm attains analyst recommendation of 2.50 out of 1-5 scale with week’s performance of 3.23%. ENDP’s institutional ownership was registered as 99.20%, while insider ownership was 0.50%.

Novavax, Inc. (NASDAQ:NVAX) persists its position slightly strong in context of buying side, while shares price ascend 2.35% during latest trading session.

Novavax reported a net loss of $79.4 million, or $0.29 per share, for the second quarter of 2016, compared to a net loss of $20.6 million, or $0.08 per share, for the second quarter of 2015. For the six months ended June 30, 2016, the net loss was $156.6 million, or $0.58 per share, compared to a net loss of $45.0 million, or $0.18 per share, for the same period in 2015.

Novavax revenue in the second quarter of 2016 decreased 82% to $2.5 million, compared to $14.0 million for the same period in 2015. Lower revenue under the BARDA contract of $13.6 million is the primary driver of this decrease. The decline in BARDA revenue in the second quarter of 2016 is the result of the one-time recognition of $7.7 million in revenue in the second quarter of 2015, and the recent advances in the Company`s seasonal influenza nanoparticle program which resulted in the wind-down of VLP influenza activities under the BARDA contract. This decrease in BARDA revenue was partially offset by $1.7 million in revenue recorded under the BMGF grant relating to our ongoing Prepare clinical trial.

Narrow down focus to other ratios, the co has current ratio of 5.10 that indicates if NVAX lies in 1.3% to 3% then it is acceptable for both active and passive investors, but sometimes its varies industry to industry. Generally, it indicates good short-term financial strength. Street is more conscious on this after SunEdison, Inc. case. To make strengthen these views, the active industry firm has Quick Ratio of 5.10, which indicates firm has sufficient short-term assets to cover its immediate liabilities. In addition, the firm has debt to equity ratio of 2.87, sometimes its remain same with long term debt to equity ratio.


About Richard Avery

He is a capital projects manager and process design engineer at a large-cap company. He has renowned MBA degree. Before joining SWR, he was a freelance writer for renounce tech websites. He is currently studying for CFP exam. Interests: Tech stocks, Economic Markets, Blue-chips.

Check Also

Valeant Pharmaceuticals International (NYSE:VRX)- Stocks Under Profitability Radar: Sanofi (NYSE:SNY)

Following analysis criteria, Valeant Pharmaceuticals International, Inc. (NYSE:VRX) attains noticeable attention, it moving down -1.92% …

Leave a Reply

Your email address will not be published. Required fields are marked *